PPT-CSL 112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients With Acute

A poAI E vent Reducin G in I schemic S yndromes II AEGISII Trial C Michael Gibson MS MD Danielle Duffy MD Gerald Chi MD Serge Korjian MD M Cecilia Bahit MD John H Alexander MD MHS A Michael Lincoff MD Mark Heise PhD Pierluigi Tricoci MD PhD MHS Jose C Nicolau MD PhD Renato Lopes MD Bela Merkely MD Basil S Lewis MD Jan H Cornel MD Jaroslaw Trebacz MD Alexander Parkhomenko MD Peter Libby MD Frank Sacks MD. Sara Fort, RN , VA-BC. Objectives. To increase . awareness of the risk of peripheral complications from infusions that . really belong . in central vascular devices.. To . prevent patient harm by educating nurses, physicians, pharmacists, and the patients by making correct choices in vascular access devices.. World Cornea Congress VII. Jessica B. Ciralsky, Kelley J. Bohm, Cecilia Nicol, Ana G. Alzaga-Fernandez, Mark I. Rosenblatt, Kimberly C. Sippel.. The authors have no relevant financial interests to disclose.. Consultant. Nephrologist. Ipswich Hospital. Beta cell . replacement: Islet and . whole pancreas transplantation. Whole pancreas usually transplanted as simultaneous kidney pancreas transplant. Should be considered for all patients with type 1 diabetes listed for kidney transplantation. Silvio E Inzucchi. Professor of . Medicine. , . Yale University School of Medicine, New Haven, CT, USA. 1. Disclosure. Consultations. and non-. financial. support . Boehringer Ingelheim, Merck, Janssen, Novo Nordisk, Sanofi/Regeron, Intarcia, Lexicon, Poxel, Takeda, Eli Lilly. FDA-Mandated CV Safety Trials. 1. TECOS. (Trial Evaluating Cardiovascular Outcomes with Sitagliptin). Clinical Outcomes with Antihyperglycemic Agents. 2. Clinical Outcomes with Sitagliptin. Study Design. 1. It remains unclear what factors contribute to favorable outcomes in this population. We aimed to determine what factors impacted outcomes in this population at our center.. METHODS. CONCLUSION. REFERENCES. CVOTs. 1. FDA CVOT Guidance—2008. Timeline of Major Diabetes. Outcomes Trials. 2. Blue. = Intensive vs standard control using same set of glucose-lowering agent(s). Purple. = Intensive control with a specific agent vs standard care. 2012-2014. (a) Denominator excludes missing/unknown causes of death. 2016 Annual Data Report, Vol . 2, ESRD. , . Ch. . 9. 2. Data Source: Special analysis using Reference Table H12. . Denominator . includes other causes of death and excludes missing/unknown causes of death (24.7% of patients have unknown or missing causes of death. Cyrus Desouza, MD. October 22, 2017. Why?. 1A. Evaluate the effect of vitamin D supplementation on incident CVD in people with . pre-diabetes.. 1B. . Establish CVD . risk in people with . pre-diabetes, defined by the modern ADA criteria.. Disclosures- None. National Health Expenditures, 2009. $. 2.5 trillion. February 6, 2014. February 6, 2014. Uwe. E. Reinhardt: . http://economix.blogs.nytimes.com/2010/12/24/fees-volume-and-spending-at-medicare/#more-94191. 1. , Andrew . P Morris. 1. , Richard Turner. 2. , Richard Fitzgerald. 2. , Rod Stables. 3. , Anita Hanson. 2. , Munir Pirmohamed. 2. 1. Department . of Biostatistics, University of Liverpool. 2. Department . TECOS Executive Committee MemberRury R. Holman, MB, ChBDiabetes Trials Unit, OCDEM Churchill Hospital, Oxford, United KingdomTECOS CoPrincipal Investigator andJoint Chair of TECOS Executive CommitteeR APOE=apolipoprotein E; CVD=cardiovascular disease; MTHFR=methylenetetrahydrofolate reductase. 1. Santos et al. . Alzheimers. Dement (. Amst. ) 2017;7:69–87; 2. . Lanctôt. et al. J Prev . Alzheimers. Diabetes Management . for the Cardiologist. Confidential. Do Not Distribute. 1. To understand the physiologic relationships between cardiovascular disease (CVD) and Type 2 Diabetes Mellitus (DM), and review the statistics behind the risk.